Monopar Therapeutics Inc (MNPR) - Total Liabilities
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has total liabilities worth $2.59 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MNPR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Monopar Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Monopar Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Monopar Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Somalogic Inc
NASDAQ:SLGC
|
USA | $68.31 Million |
|
Guangdong Qunxing Toys Joint-Stock Co Ltd
SHE:002575
|
China | CN¥102.80 Million |
|
Hunan Huasheng Co Ltd
SHG:600156
|
China | CN¥460.49 Million |
|
Guangzhou Jinyi Media Corp
SHE:002905
|
China | CN¥2.19 Billion |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $94.61 Million |
|
Quadient SA
PA:QDT
|
France | €1.40 Billion |
|
Hyundai Green Food Co. Ltd.
KO:453340
|
Korea | ₩325.87 Billion |
|
TCI Co Ltd
TWO:8436
|
Taiwan | NT$4.93 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Monopar Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MNPR stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 56.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Monopar Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Monopar Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.89 Million | -44.99% |
| 2024-12-31 | $5.25 Million | +198.98% |
| 2023-12-31 | $1.76 Million | -43.98% |
| 2022-12-31 | $3.14 Million | +98.50% |
| 2021-12-31 | $1.58 Million | +34.32% |
| 2020-12-31 | $1.18 Million | +62.49% |
| 2019-12-31 | $724.16K | +81.24% |
| 2018-12-31 | $399.55K | +28.12% |
| 2017-12-31 | $311.87K | +383.44% |
| 2016-12-31 | $64.51K | -12.64% |
| 2015-12-31 | $73.84K | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more